Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8800054 | 0.85 | MTNR1A (0.47) | MTNR1AMTNR1BSNCAMEN1NPC1 | |
| SCHEMBL2479169 | 0.84 | HTR7 (0.47) | HTR7 | |
| SCHEMBL31314511 | 0.83 | MCL1 (0.47) | MTNR1AMTNR1BNPC1HDAC3HDAC1 | |
| SCHEMBL30672858 | 0.83 | PLG (0.46) | KMT2AHTR7 | |
| SCHEMBL2124040 | 0.83 | PLG (0.46) | KMT2AHTR7 | |
| SCHEMBL2767840 | 0.82 | HDAC8 (0.57) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL23902730 | 0.81 | GLS (0.46) | HTR7 | |
| SCHEMBL2263041 | 0.81 | GLS (0.46) | NPC1HTR7 | |
| SCHEMBL30241520 | 0.81 | GLS (0.46) | HTR7 | |
| SCHEMBL3355607 | 0.81 | HTR7 (0.49) | MTNR1AMTNR1BMEN1KMT2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008832-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | disclosed |
| EP-0779887-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODIESTERASE INHIBITING ACTIVITY | OTSUKA PHARMA CO LTD (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5998437-A | ARTERIOSCLEROSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0779887-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| WO-1997003070-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008832-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | MTNR1A 4352/4885MTNR1B 3978/4885HTR2C 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.